According to this study, EGFR inhibitors such as gefitinib and afatinib demonstrated high tumor-to-non-tumor IC50 ratios (approximately 400 and 100, respectively) in vitro and suppressed tumor growth in xenograft FANCA-HNSCC in vivo models without inducing significant hematopoietic toxicity in FANCA-deficient mice. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.